Oscar's Tumor DNA Report | Mutation-to-Treatment Logic

When Oscar was diagnosed, the cancer felt like one thing: TCC. Bladder. Trigone. Maybe six months. Then the DNA report came back, and the cancer became more specific — not less serious, not less frightening, but more knowable.

Separately, a BRAF mutation test was positive in April 2025, prior to the oncology consult — supporting the urothelial/TCC picture before the full tumor DNA map arrived.

The tumor DNA test was a Vidium SearchLight DNA profile: Accession SL25-000232, received 05/05/25, reported 05/12/25. Site: trigonal urethral. Diagnosis on the report: urothelial carcinoma. Matching drugs listed on the report (including olaparib, platinum, trametinib, sirolimus, and others) were framed for us as a map for questions with my oncologist — not prescriptions to start on our own.

Finding	Plain meaning	Treatment question	Evidence tier
BRCA1 copy-number loss	Possible DNA-repair weakness	Should platinum chemo and PARP inhibition be considered?	Platinum B PARP C
PDGFRA copy-number gain	Possible growth-factor / receptor signaling	Is RTK targeting (e.g. Palladia/toceranib) rational?	B/C
NF1 p.Ser1045fs	Possible loss of a MAPK pathway brake	Is MEK inhibition (e.g. trametinib) rational if disease progresses?	B/C
TSC2 copy-number loss	Possible mTOR pathway activation	Is mTOR inhibition (e.g. sirolimus) worth discussing?	C/D
ABCB1-1Δ	MDR1 / drug-sensitivity genotype	Any dosing-caution questions for my oncologist?	Not detected
BRAF+	Common canine TCC mutation test — positive April 2025 (prior to oncology consult)	Supported urothelial/TCC diagnosis and early planning	Confirmed

Finding

Plain meaning

Treatment question

Evidence tier

BRCA1 copy-number loss

Possible DNA-repair weakness

Should platinum chemo and PARP inhibition be considered?

Platinum B PARP C

PDGFRA copy-number gain

Possible growth-factor / receptor signaling

Is RTK targeting (e.g. Palladia/toceranib) rational?

B/C

NF1 p.Ser1045fs

Possible loss of a MAPK pathway brake

Is MEK inhibition (e.g. trametinib) rational if disease progresses?

B/C

TSC2 copy-number loss

Possible mTOR pathway activation

Is mTOR inhibition (e.g. sirolimus) worth discussing?

C/D

ABCB1-1Δ

MDR1 / drug-sensitivity genotype

Any dosing-caution questions for my oncologist?

Not detected

BRAF+

Common canine TCC mutation test — positive April 2025 (prior to oncology consult)

Supported urothelial/TCC diagnosis and early planning

Confirmed

Logic chains (questions, not prescriptions)

BRCA1

DNA repair weakness→platinum / PARP question→carboplatin / olaparib discussion

PDGFRA

Growth signaling→RTK question→Palladia discussion

NF1

MAPK brake failure→MEK question→trametinib later

TSC2

mTOR signaling→mTOR question→sirolimus Rx/discussed May 2026; never started

What the report did not do. It did not guarantee a response, prove future metastases would share the same drivers, remove the need for monitoring, make supplements safe, or make every plausible drug worth stacking. Caption for any diagram: “This explains why we asked certain questions. It is not a treatment protocol.”

The DNA Report Did Not Give Us a Cure. It Gave Us a Map.

Logic chains (questions, not prescriptions)

BRCA1

PDGFRA

NF1

TSC2